Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 2/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.78 |
| ▸ | AR | P10275 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.78 |
| ▸ | DRD1 | P21728 | 2/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705950 | 0.94 | ESR1 (0.69) | ESR1LMNACYP1A2PGRCHRM2 | |
| Hexestrol SCHEMBL154885 | 0.88 | ESR1 (1.00) | ESR1LMNACYP1A2PGRCHRM2 | |
| Hexestrol SCHEMBL154886 | 0.88 | ESR1 (1.00) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL30402896 | 0.84 | ESR1 (0.75) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL12995870 | 0.84 | ESR1 (0.61) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL23676945 | 0.83 | ESR1 (0.59) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL12872219 | 0.82 | ESR1 (0.58) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL1323678 | 0.82 | ESR1 (0.78) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL21709894 | 0.81 | ESR1 (0.52) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL18926564 | 0.80 | ESR1 (0.83) | ESR1LMNACYP1A2PGRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928945-A1 | THERMOPLASTIC POLYMER ADDITIVE COMPOSITONS | Colormatrix Europe, Ltd. (GB) | 2008-06-11 | — | — | EP | claimed |
| WO-2007039719-A1 | THERMOPLASTIC POLYMER ADDITIVE COMPOSITONS | COLORMATRIX EUROPE LIMITED (GB) | 2007-04-12 | — | — | WO | claimed |
| US-12180428-B2 | Methods of using ionic liquids as paraffin inhibitors, pour point depressants and cold flow improvers | Baker Hughes Holdings, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230384674-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| WO-2023210520-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, AND COMPOUND | 東京応化工業株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023171743-A1 | RESIST COMPOSITION, METHOD FOR FORMING RESIST PATTERN, COMPOUND, AND POLYMER | 東京応化工業株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023171739-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, COMPOUND, AND POLYMER COMPOUND | 東京応化工業株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023140364-A1 | RESIST COMPOSITION, METHOD FOR FORMING RESIST PATTERN, COMPOUND, AND POLYMER | 東京応化工業株式会社 | 2023-07-27 | — | — | WO | disclosed |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210069208-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10889611-B2 | Sialyltransferase inhibitors and uses thereof | ACADEMIA SINICA (TW) | 2021-01-12 | — | — | US | disclosed |
| US-20200017790-A1 | METHODS OF USING IONIC LIQUIDS AS PARAFFIN INHIBITORS, POUR POINT DEPRESSANTS AND COLD FLOW IMPROVERS | BAKER HUGHES HOLDINGS LLC | 2020-01-16 | — | — | US | disclosed |
| EP-2707776-B1 | POSITIVE RESIST COMPOSITION, AND RESIST FILM, RESIST-COATED MASK BLANK AND RESIST PATTERN FORMING METHOD EACH USING THE COMPOSITION | FUJIFILM CORP (JP) | 2017-07-19 | — | — | EP | disclosed |
| WO-2014133187-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE, ELECTRONIC DEVICE AND COMPOUND | FUJIFILM CORPORATION (JP) | 2014-09-04 | — | — | WO | disclosed |
| EP-1353225-B1 | Radiation sensitive composition and compound | FUJIFILM CORP (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2012153869-A1 | POSITIVE RESIST COMPOSITION, AND RESIST FILM, RESIST-COATED MASK BLANK, RESIST PATTERN FORMING METHOD AND PHOTOMASK EACH USING THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2012-11-15 | — | — | WO | disclosed |
| EP-1838821-A1 | LUBRICATING OIL COMPOSITION | Shell Internationale Research Maatschappij B.V. (NL) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006061436-A1 | LUBRICATING OIL COMPOSITION | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ESR1 3454/4885LMNA 1539/4885CYP1A2 4865/4885 |
| US-10889611-B2 | Sialyltransferase inhibitors and uses thereof | ST6GAL1, NEU1, GALNT1 | ESR1 4026/4885LMNA 4496/4885CYP1A2 3815/4885 |
| US-20210069208-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ESR1 3383/4885LMNA 1595/4885CYP1A2 4864/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | ESR1 3454/4885LMNA 1539/4885CYP1A2 4865/4885 |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | RRM2, RRM2B, RRM1 | ESR1 4794/4885LMNA 4278/4885CYP1A2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.